Latest research on Harvoni

Sofosbuvir is a medication used as part of combination therapy to treat hepatitis C virus (HCV) infection or HCV and HIV co-infection. Sofosbuvir is nucleotide analog inhibitor, which specifically inhibits HCV NS5B polymerase. Sofosbuvir was approved by the FDA in December 2013, and is marketed under the brand name Sovaldi.

Harvoni indications

Therefore, for genotype 2 patients with cirrhosis, Harvoni is the most cost-effective treatment. [source, 2015]
Only when the sofosbuvir price is reduced by at least 30 %, olysio + sovaldi and sofosbuvir + peginterferon + ribavirin can achieve cost-effectiveness compared to Harvoni or Viekira Pak for genotype 1 patients. [source, 2015]
Further, increasing SVR for sofosbuvir-based treatments by 10 % does make them cost-effective compared to Harvoni and Viekira Pak for genotype 1 patients, and reducing SVR for Harvoni and Viekira Pak by 10 % also makes sofosbuvir-based treatments cost-effective. [source, 2015]
Thus, for genotype 1 patients, a reduction in sofosbuvir price can improve the cost-effectiveness of sofosbuvir-based treatments compared to the alternatives of Harvoni and Viekira Pak. [source, 2015]
For Viekira Pak and sofosbuvir + peginterferon + ribavirin, compared to Harvoni, they both have roughly a 0.50 probability of being effective according to figure. [source, 2015]
Our analyses show that Viekira Pak is cost-effective for genotype 1 patients without cirrhosis, while Harvoni is cost-effective for genotype 1 patients with cirrhosis. [source, 2015]
We found that for genotype 1 patients, sofosbuvir-based treatments are not cost-effective compared to Viekira Pak and Harvoni. [source, 2015]
At the end of 2014 of effective interferon-free, hepatitis C treatments with Gilead’s Sovaldi, Gilead’s Harvoni and AbbVie’s Veikira Pak has been introduced. [source, 2015]